[Newsmp] In the first quarter, when the Omicron variant of COVID-19 was severe, all major pharmaceutical companies achieved good results.
Newsmp compiled the disclosures of the five major pharmaceutical companies, and it was found that the average sales growth rate of them in the first quarter was 19.7%. Operating profit and net profit also surged 51.8% and 182.6%, respectively.
GC Pharma showed the most outstanding performance in the first quarter, with sales soaring 47.7% year-on-year to KRW 416.9 billion, exceeding the KRW 400 billion mark.
In addition, GC Pharma’s operating profit, which stood at KRW 5 billion in the first quarter of last year, soared 736.0% to KRW 41.8 billion, but its net profit was KRW 18 billion, not much different from the same period last year.
Hanmi Pharmaceutical also showed remarkable growth. Sales rose 18.8% to KRW 321.1 billion, exceeding KRW 300 billion while operating profit increased 29.1% to KRW 38.7 billion and net profit 6.9% to KRW 24.8 billion.
Daewoong Pharmaceutical posted sales of KRW 272.2 billion with 12.6% growth while operating profit surged 32.6% to KRW 26.8 billion, and net profit, which recorded a deficit of KRW 23.3 billion last year, turned into a surplus of KRW 17.5 billion.
Yuhan Corporation also recorded double-digit sales growth of 12.3%, achieving nearly KRW 400 billion (KRW 397.7 billion) in sales. However, operating profit was only KRW 5 billion, but net profit jumped 217.8% year-on-year to KRW 88.8 billion, approaching the KRW 100 billion mark.
In the meantime, Chong Kun Dang’s sales rose 8.8% year-on-year to KRW 338 billion, the only one among the five pharmaceutical companies with a single-digit sales growth rate. Operating profit also increased 8.6% to KRW 24.3 billion and the increase remained in the single digits, but net profit gained 27.2%, nearly 30% to KRW 17.2 billion.
